Literature DB >> 30229259

Towards rational design of RAD51-targeting prodrugs: platinumIV-artesunate conjugates with enhanced cytotoxicity against BRCA-proficient ovarian and breast cancer cells.

Shuren Zhang1, Hao Yuan, Yan Guo, Kun Wang, Xiaoyong Wang, Zijian Guo.   

Abstract

Two PtIV-artesunate anticancer prodrugs that target RAD51, a crucial protein in homologous recombination mediating the sensitivity of cancer cells to DNA-damaging agents, were designed; their cytotoxicities against BRCA-proficient ovarian and breast cancer cells are significantly higher than those of cisplatin.

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 30229259     DOI： 10.1039/c8cc06576d

Source DB:  PubMed          Journal:  Chem Commun (Camb)        ISSN： 1359-7345            Impact factor:   6.222


  4 in total

Review 1.  Exploring the Potential of Metallodrugs as Chemotherapeutics for Triple Negative Breast Cancer.

Authors:  Nazia Nayeem; Maria Contel
Journal:  Chemistry       Date:  2021-05-05       Impact factor: 5.020

2.  Artesunate Regulates Neurite Outgrowth Inhibitor Protein B Receptor to Overcome Resistance to Sorafenib in Hepatocellular Carcinoma Cells.

Authors:  Wubin He; Xiaoxu Huang; Bradford K Berges; Yue Wang; Ni An; Rongjian Su; Yanyan Lu
Journal:  Front Pharmacol       Date:  2021-02-25       Impact factor: 5.810

3.  Preclinical Evaluation of Artesunate as an Antineoplastic Agent in Ovarian Cancer Treatment.

Authors:  Anthony McDowell; Kristen S Hill; J Robert McCorkle; Justin Gorski; Yilin Zhang; Ameen A Salahudeen; Fred Ueland; Jill M Kolesar
Journal:  Diagnostics (Basel)       Date:  2021-02-26

4.  An intramolecular photoswitch can significantly promote photoactivation of Pt(iv) prodrugs.

Authors:  Zhiqin Deng; Cai Li; Shu Chen; Qiyuan Zhou; Zoufeng Xu; Zhigang Wang; Houzong Yao; Hajime Hirao; Guangyu Zhu
Journal:  Chem Sci       Date:  2021-04-01       Impact factor: 9.825
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.